

図4 狂犬病ウイルス中和活性を有するヒトFabクローン(EP5G3, GD2D12)のV_k(A),
VH(B)領域のアミノ酸配列

(A)		FR1	CDR1	FR2	CDR2
EP5G3	--	VMTQSPATLSLSPGERA TLSC	<u>RASQSVRNYLA</u>	WYQQKPGQA P RLLIY	<u>GASNRAT</u>
GD2D12	EL...	LS.PVTL.QP.SI..	<u>.S...LIHSGNTYLN</u>	.F.R...S.R...	<u>KV.D.D.DS</u>
EP5G3		FR3	CDR3	FR4	
GD2D12	GIPARFSGSGGTFTLTISLEPEDFAVYY	<u>CQQRSDWPLS</u>	FGQGTKLEIKRT		
	.V.D.....K.RV..A.VG...	<u>.L.GTH...RT</u>		
(B)		FR1	CDR1	FR2	CDR2
EP5G3	GPAWEVPETLPVQPLDSPSV	<u>AMACT</u>	GVRQAPGKGLEWVA	<u>VISYDGSNKYYADSVKGV</u>	
GD2D12	VVQPGRSLR.SCAASGFTFS	<u>SY.MH</u>	W.....	
EP5G3		FR3	CDR3	FR4	
GD2D12	RFT I SRDNSKNTLYLQMNSLRAEDTAVYYC	<u>AKDSNSGSYY AHDLGY- - -</u>	<u>WGQGLVTV-</u>		
	R.....	<u>.R.KALAA RRGYYYYGTDV</u>S		

図5 確立された3種類のヒト型Fab分子が認識するRV抗原特異性




図6 ヒト型Fab分子投与による狂犬病ウイルス街1088株に対する
防衛効果(マウス生存率)





図7 Fabから完全型IgG分子への変換

(A)



(B)







図8 完全型IgG抗体3G7の大量培養による精製



- 1, IgGTC3G7, non-reducing
- 2, Human IgG, non-reducing
- 3, IgGTC3G7, reducing
- 4, Human IgG, reducing

図9 完全型抗体IgG 3G7と1A10の狂犬病ウイルス株間との反応性

	CVS	HEP-Flury	ERA	1088
Complete IgG 3G7	++	++	+	++
Complete IgG 1A10	-	-	-	-
Anti-N MoAb	++	++	++	++

	Infection at moi=5
TC3G7 IgG	
TC1A10 IgG	
anti-RV N mouse mAb	